On the opposite, a specific inhibition of DNMT1/DMAP1 interaction increased the temolozomide response in glioma cells, suggesting that inhibition of specific DNMT-including complexes could be used in the future in combination with classical chemotherapeutic agents. Here, DNMT1 is linked to central nervous system cancer.